Ret Receptor: Functional Consequences of Oncogenic Rearrangements.
Abstract
The overall goals of this proposal are to characterize the gene product of a novel oncogene ret/ptc2. This protein is a fusion of the RIalpha subunit of cAMP-dependent protein kinase and the kinase domain of a receptor tyrosine kinase. The ligand for the RET receptor is still unknown, however, this gene is associated with many inherited dominant cancers such as MEN2A, MEN2B, and Hirschprung's disease. Ret/ptc2 is a constitutively active form of the RET receptor, and we believe it will be a prototype for other oncogene receptor tyrosine kinases. Our goals are to express large amounts of ret/ptc2 to establish the structural basis for its activation, to establish how the RET receptor functions in vivo by identifying the proteins it interacts with, and to model the ret kinase domain and map the sites of mutation that are known to be associated with various diseases. We are also constructing chimeras that resemble ret/ptc2 using the kinase domains of the EGF receptor and the insulin receptor.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1995
- Accession Number
- ADA302659
Entities
People
- Susan S. Taylor
Organizations
- University of California, San Diego